Brought to you by 
Spectral Diagnostics and Metra Biosystems back out of merger
13 Jul 1999
Executive Summary
Spectral Diagnostics (cardiac POC tests) will merge with Metra Biosystems (POC metabolic bone disease tests) in a mostly stock transaction; Spectral shareholders will own 51% of the new company.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Chemistry, Immunoassay
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Spectral Diagnostics and Metra Biosystems back out of merger
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice